This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 617 |
influenza viruses | 404 |
pandemic influenza | 299 |
seasonal influenza | 261 |
like illness | 189 |
respiratory viruses | 187 |
public health | 182 |
acute respiratory | 176 |
influenza surveillance | 173 |
influenza vaccine | 154 |
respiratory tract | 143 |
hong kong | 135 |
avian influenza | 130 |
respiratory infections | 128 |
surveillance system | 113 |
years old | 107 |
virus infection | 105 |
united states | 104 |
influenza infection | 97 |
influenza vaccination | 95 |
ili cases | 94 |
respiratory illness | 93 |
sore throat | 89 |
surveillance data | 85 |
age groups | 84 |
influenza pandemic | 81 |
influenza season | 79 |
respiratory syncytial | 78 |
ili patients | 75 |
respiratory infection | 75 |
respiratory virus | 73 |
syncytial virus | 69 |
ili surveillance | 68 |
world health | 67 |
swine influenza | 67 |
sentinel surveillance | 67 |
health organization | 67 |
infectious diseases | 65 |
mdck cells | 65 |
hajj pilgrims | 64 |
health care | 64 |
infected cells | 62 |
respiratory pathogens | 61 |
human influenza | 61 |
virus infections | 61 |
ili surge | 60 |
least one | 59 |
disease control | 59 |
respiratory symptoms | 59 |
amino acid | 59 |
immune response | 58 |
age group | 58 |
severe acute | 57 |
ili incidence | 56 |
risk factors | 55 |
highly pathogenic | 55 |
influenza vaccines | 55 |
confirmed influenza | 54 |
viral infections | 52 |
cell culture | 50 |
influenza activity | 49 |
virus replication | 49 |
real time | 47 |
viruses isolated | 47 |
influenza epidemics | 46 |
time pcr | 46 |
time rt | 46 |
case definition | 46 |
surveillance systems | 45 |
tract infections | 44 |
respiratory viral | 43 |
ae log | 43 |
viral respiratory | 43 |
first wave | 43 |
influenza cases | 42 |
pathogenic avian | 42 |
previously described | 41 |
like incidence | 41 |
significantly higher | 41 |
lower respiratory | 40 |
copyright holder | 40 |
upper respiratory | 40 |
granted medrxiv | 40 |
preventive measures | 40 |
author funder | 40 |
viral shedding | 40 |
influenza seasons | 40 |
logistic regression | 40 |
influenza ili | 39 |
household transmission | 39 |
sari cases | 39 |
sentinel sites | 39 |
syndromic surveillance | 38 |
air pollution | 38 |
cord uid | 38 |
school closure | 38 |
antibody response | 38 |
viral load | 38 |
doc id | 38 |
pandemic virus | 38 |
icu admissions | 37 |
influenza transmission | 37 |
detection rate | 37 |
national influenza | 37 |
case definitions | 37 |
present study | 36 |
polymerase chain | 36 |
influenza epidemic | 36 |
vaccine strain | 35 |
chain reaction | 35 |
gene segments | 35 |
general population | 35 |
infectious disease | 35 |
virus isolation | 35 |
weight loss | 35 |
study period | 34 |
epidemic period | 34 |
antiviral treatment | 34 |
new york | 33 |
growth rate | 33 |
fast set | 33 |
respiratory disease | 33 |
samples collected | 33 |
viral infection | 33 |
human metapneumovirus | 33 |
young children | 33 |
antibody titers | 32 |
children aged | 32 |
applied biosystems | 32 |
influenza infections | 32 |
days post | 31 |
phylogenetic analysis | 31 |
icu data | 31 |
respiratory syndrome | 31 |
ili data | 31 |
epithelial cells | 31 |
cruise ship | 31 |
case detection | 31 |
median age | 31 |
early detection | 31 |
confirmed cases | 30 |
runny nose | 30 |
secondary ili | 30 |
positive rate | 30 |
clinical symptoms | 30 |
school breaks | 29 |
immune responses | 29 |
ili episodes | 29 |
clinical rate | 29 |
clinical signs | 29 |
severe disease | 28 |
southern china | 28 |
tested positive | 28 |
chicken eggs | 28 |
vaccine effectiveness | 28 |
statistically significant | 28 |
live attenuated | 28 |
adjuvanted vaccine | 28 |
social distancing | 28 |
pdm virus | 28 |
virus strains | 28 |
ha gene | 28 |
version posted | 27 |
disease surveillance | 27 |
antiviral drugs | 27 |
influenza outbreaks | 27 |
performed using | 27 |
body weight | 27 |
intensive care | 27 |
seasonal threshold | 27 |
total number | 27 |
based surveillance | 27 |
virus transmission | 26 |
human respiratory | 26 |
ili case | 26 |
made available | 26 |
winter breaks | 26 |
symptom onset | 26 |
ae lg | 26 |
pandemic vaccine | 26 |
influenza strains | 26 |
predictive value | 26 |
ili definition | 26 |
study design | 25 |
nasal washes | 25 |
informed consent | 25 |
household members | 25 |
novel coronavirus | 25 |
nasal swabs | 25 |
data collection | 25 |
cleavage site | 25 |
confidence interval | 25 |
excess ili | 25 |
within hours | 25 |
crew members | 25 |
virus detection | 25 |
clinical samples | 25 |
like illnesses | 24 |
secondary cases | 24 |
parainfluenza viruses | 24 |
virus ns | 24 |
severe cases | 24 |
detection rates | 24 |
household contacts | 24 |
clinical characteristics | 24 |
origin influenza | 24 |
sari patients | 24 |
mdck pf | 24 |
international license | 24 |
rsv infection | 24 |
viral rna | 24 |
less likely | 24 |
cohort study | 24 |
factors associated | 24 |
hand hygiene | 24 |
year old | 24 |
multiplex pcr | 23 |
cell index | 23 |
embryonated chicken | 23 |
older adults | 23 |
positive samples | 23 |
cytopathic effect | 23 |
severe influenza | 23 |
cruise ships | 23 |
cell lines | 23 |
na genes | 22 |
viruses detected | 22 |
regression model | 22 |
based model | 22 |
case patient | 22 |
case counts | 22 |
weekly ili | 22 |
inactivated influenza | 22 |
viruses circulating | 22 |
per year | 22 |
ae ae | 22 |
clinical specimens | 22 |
respiratory diseases | 22 |
throat swabs | 22 |
high yield | 22 |
passive immunotherapy | 22 |
southern hemisphere | 22 |
human seasonal | 21 |
vaccination status | 21 |
epidemic curve | 21 |
primary care | 21 |
internal genes | 21 |
systematic review | 21 |
fatality rate | 21 |
standard deviation | 21 |
like viruses | 21 |
human macrophages | 21 |
clinical data | 21 |
medrxiv preprint | 21 |
reverse genetics | 21 |
national institute | 21 |
virus isolates | 21 |
influenza positive | 20 |
ari episodes | 20 |
aged years | 20 |
cell death | 20 |
ae ml | 20 |
log tcid | 20 |
reverse transcription | 20 |
pcr assay | 20 |
among pilgrims | 20 |
tract infection | 20 |
isolation rate | 20 |
clinical case | 20 |
parainfluenza virus | 20 |
one virus | 20 |
early warning | 20 |
moving average | 20 |
results suggest | 20 |
vaccine candidates | 20 |
pdm viruses | 20 |
bacterial infection | 20 |
mdck cell | 20 |
resistant viruses | 20 |
sentinel hospitals | 20 |
virus titers | 20 |
nasopharyngeal swabs | 20 |
vaccine production | 20 |
pandemic strain | 20 |
set infa | 20 |
versus ae | 20 |
infected patients | 19 |
peer review | 19 |
antigenic cartography | 19 |
antigenic drift | 19 |
vaccine strains | 19 |
febrile respiratory | 19 |
circulating influenza | 19 |
infections among | 19 |
respiratory samples | 19 |
regression models | 19 |
ic values | 19 |
geometric mean | 19 |
chicken embryos | 19 |
saudi arabia | 19 |
virus infected | 19 |
novel influenza | 19 |
severe illness | 19 |
virus type | 19 |
confirmed covid | 19 |
cell cultures | 19 |
transport medium | 19 |
attenuated influenza | 19 |
patients infected | 18 |
solar radiation | 18 |
sample collection | 18 |
na gene | 18 |
oseltamivir resistance | 18 |
ae versus | 18 |
pf cells | 18 |
data analysis | 18 |
sentinel ducks | 18 |
serum samples | 18 |
global influenza | 18 |
ili visits | 18 |
study population | 18 |
school students | 18 |
pandemic potential | 18 |
hospital admissions | 18 |
laboratory testing | 18 |
nucleic acid | 18 |
resistant virus | 18 |
australian hajj | 18 |
disease burden | 18 |
may also | 18 |
fluor tm | 18 |
among children | 18 |
primary case | 18 |
time reverse | 18 |
increased risk | 18 |
attack rate | 18 |
previous studies | 18 |
significant differences | 18 |
antibody responses | 18 |
pandemic wave | 18 |
tm assay | 18 |
antiviral resistance | 17 |
care unit | 17 |
young adults | 17 |
neuraminidase inhibitor | 17 |
migratory ducks | 17 |
swab specimens | 17 |
na mutation | 17 |
human bocavirus | 17 |
ili symptoms | 17 |
clinical trial | 17 |
laiv candidates | 17 |
ili sentinel | 17 |
ffp respirators | 17 |
rhinovirus enterovirus | 17 |
pcr assays | 17 |
immune system | 17 |
among sari | 17 |
day post | 17 |
ae ng | 17 |
viral loads | 17 |
swine origin | 17 |
regression analysis | 17 |
nasal swab | 17 |
infection control | 17 |
pneumococcal vaccine | 16 |
disease severity | 16 |
ha cleavage | 16 |
canine kidney | 16 |
one week | 16 |
neuraminidase inhibitors | 16 |
health surveillance | 16 |
among patients | 16 |
relative humidity | 16 |
infected mice | 16 |
virus circulation | 16 |
time series | 16 |
reverse transcriptase | 16 |
mean age | 16 |
detect influenza | 16 |
higher risk | 16 |
two weeks | 16 |
ns protein | 16 |
missing data | 16 |
clinical trials | 16 |
clinical presentation | 16 |
case patients | 16 |
controlled trial | 16 |
second vaccination | 16 |
specific igy | 16 |
suspected cases | 16 |
secondary bacterial | 16 |
icu admission | 16 |
elderly people | 16 |
vaccination coverage | 16 |
reactive antibody | 16 |
influenza vii | 16 |
high risk | 16 |
predicting influenza | 16 |
results showed | 16 |
among hajj | 16 |
viral culture | 15 |
statistical analysis | 15 |
human infection | 15 |
influenza like | 15 |
influenza sentinel | 15 |
bacterial infections | 15 |
including influenza | 15 |
national health | 15 |
aged children | 15 |
using data | 15 |
hours post | 15 |
described previously | 15 |
incidence rates | 15 |
inactivated vaccine | 15 |
hemagglutination inhibition | 15 |
average number | 15 |
significantly lower | 15 |
south africa | 15 |
viral pathogens | 15 |
rapid antigen | 15 |
control measures | 15 |
rights reserved | 15 |
darby canine | 15 |
antiviral drug | 15 |
sequence alignment | 15 |
summer breaks | 15 |
sequence analysis | 15 |
one respiratory | 15 |
specimen collection | 15 |
surveillance network | 15 |
health service | 15 |
pb gene | 15 |
sandwich elisa | 15 |
important role | 15 |
small number | 15 |
statistical analyses | 15 |
north america | 15 |
doubling time | 15 |
swine flu | 15 |
data sources | 15 |
hajj pilgrimage | 14 |
well plates | 14 |
previously reported | 14 |
reproduction number | 14 |
positive patients | 14 |
two doses | 14 |
antigenic sites | 14 |
allergenic pollen | 14 |
room temperature | 14 |
allowed without | 14 |
alveolar epithelial | 14 |
human adenovirus | 14 |
sudden onset | 14 |
commonly detected | 14 |
coronavirus disease | 14 |
inhibition assay | 14 |
symptomatic case | 14 |
drug resistance | 14 |
positive predictive | 14 |
confirmed case | 14 |
medical research | 14 |
poisson regression | 14 |
without permission | 14 |
zhejiang province | 14 |
classical swine | 14 |
ns gene | 14 |
acquired pneumonia | 14 |
circulating strains | 14 |
viral isolation | 14 |
xtd tm | 14 |
military health | 14 |
step rt | 14 |
confidence intervals | 14 |
acid changes | 14 |
direct contact | 14 |
resplex ii | 14 |
virus positive | 14 |
reuse allowed | 14 |
mortality rate | 14 |
fatal cases | 14 |
pilot project | 14 |
posted june | 14 |
hospitalized patients | 14 |
table shows | 14 |
gene segment | 14 |
developing countries | 14 |
intensity thresholds | 14 |
pandemic flu | 14 |
allantoic fluid | 14 |
also found | 14 |
household incidence | 13 |
moving epidemic | 13 |
seeking behavior | 13 |
amino acids | 13 |
serial interval | 13 |
healthcare workers | 13 |
symptomatic cases | 13 |
posted april | 13 |
bacterial pneumonia | 13 |
closely related | 13 |
monoclonal antibodies | 13 |
protective immunity | 13 |
epidemic threshold | 13 |
antiviral agents | 13 |
blood samples | 13 |
clinical features | 13 |
first vaccination | 13 |
innate immune | 13 |
gene expression | 13 |
vaccine groups | 13 |
laboratory confirmed | 13 |
peak activity | 13 |
time period | 13 |
human transmission | 13 |
plaque assay | 13 |
exponential growth | 13 |
meteorological variables | 13 |
ex vivo | 13 |
healthy children | 13 |
sensing receptors | 13 |
viral replication | 13 |
per week | 13 |
viral etiology | 13 |
laboratory results | 13 |
medical care | 13 |
detecting influenza | 13 |
wild type | 13 |
growth rates | 13 |
community cohort | 13 |
phylogenetic trees | 13 |
doubling times | 13 |
ili activity | 13 |
among ili | 13 |
syndrome coronavirus | 13 |
adults hospitalized | 13 |
total pollen | 13 |
pneumococcal vaccination | 13 |
viral titers | 13 |
treated mice | 13 |
pandemic strains | 13 |
virus strain | 13 |
within days | 13 |
epidemic method | 13 |
respiratory specimens | 13 |
control chart | 13 |
indoor air | 13 |
control group | 13 |
general practitioners | 13 |
human coronavirus | 13 |
pandemic scenario | 13 |
surveillance program | 13 |
low pathogenic | 13 |
disease outbreaks | 13 |
human lung | 13 |
sample size | 13 |
written informed | 13 |
pandemic viruses | 13 |
epidemiological data | 13 |
emerging infectious | 13 |
hpai virus | 13 |
immunized mice | 13 |
receptor binding | 13 |
influenza outbreak | 13 |
new influenza | 13 |
rgy sub | 13 |
novel swine | 13 |
vaccine uptake | 13 |
high rates | 13 |
samples tested | 13 |
true prevalence | 13 |
high levels | 13 |
full genome | 13 |
common respiratory | 12 |
second dose | 12 |
household ili | 12 |
current week | 12 |
nasopharyngeal swab | 12 |
among australian | 12 |
reproductive number | 12 |
clinical rates | 12 |
erk activation | 12 |
latent period | 12 |
primary human | 12 |
multiplex assay | 12 |
three weeks | 12 |
study also | 12 |
health behavior | 12 |
healthy controls | 12 |
influenza neuraminidase | 12 |
school children | 12 |
rna extraction | 12 |
surveillance study | 12 |
statistical significance | 12 |
nasal congestion | 12 |
associated hospitalizations | 12 |
rgvac ins | 12 |
prior protection | 12 |
household compound | 12 |
community transmission | 12 |
ae years | 12 |
innate sensing | 12 |
classical reassortment | 12 |
antigenic changes | 12 |
virus vaccine | 12 |
data collected | 12 |
hi antibody | 12 |
study showed | 12 |
care facilities | 12 |
genetic characteristics | 12 |
ae lm | 12 |
significantly reduced | 12 |
chart method | 12 |
viral detection | 12 |
type virus | 12 |
health research | 12 |
neuraminidase assay | 12 |
ct values | 12 |
infectious virus | 12 |
haemophilus influenzae | 12 |
vaccine efficacy | 12 |
level allergenic | 12 |
entry screening | 12 |
vaccine administration | 12 |
ev species | 12 |
upper limit | 12 |
elderly persons | 12 |
sensitivity analysis | 12 |
wt virus | 12 |
higher proportion | 11 |
health authorities | 11 |
patients hospitalized | 11 |
hi titres | 11 |
recent study | 11 |
phylogenetic analyses | 11 |
rapid detection | 11 |
endothelial cells | 11 |
signaling pathways | 11 |
ili events | 11 |
different subtypes | 11 |
average epidemic | 11 |
peripheral blood | 11 |
per person | 11 |
ethics committee | 11 |
poyang lake | 11 |
infectious agents | 11 |
detection limit | 11 |
health system | 11 |
illness among | 11 |
infection among | 11 |
ad hoc | 11 |
first pandemic | 11 |
oseltamivir carboxylate | 11 |
mem method | 11 |
ii cells | 11 |
rgvac sub | 11 |
laboratory confirmation | 11 |
detection kit | 11 |
virus gene | 11 |
even though | 11 |
transmission model | 11 |
school aged | 11 |
bronchoalveolar lavage | 11 |
competing interests | 11 |
neutralizing antibodies | 11 |
cell line | 11 |
host response | 11 |
influenza antigenic | 11 |
syndromic case | 11 |
many countries | 11 |
ah pdm | 11 |
european countries | 11 |
immunotherapy program | 11 |
highly sensitive | 11 |
study conducted | 11 |
future studies | 11 |
placebo group | 11 |
north american | 11 |
three consecutive | 11 |
multiple sequence | 11 |
health centers | 11 |
genome sequences | 11 |
analysis using | 11 |
adult patients | 11 |
molecular epidemiology | 11 |
reassortant viruses | 11 |
joining method | 11 |
new virus | 11 |
influenza type | 11 |
research agenda | 11 |
first time | 11 |
infection fatality | 11 |
results show | 11 |
unexplained pneumonia | 11 |
swine viruses | 11 |
hajj season | 11 |
slightly lower | 11 |
frequently detected | 11 |
influenza among | 11 |
among household | 11 |
lab data | 11 |
old embryonated | 11 |
care utilization | 11 |
may lead | 11 |
time lag | 11 |
tissue culture | 11 |
may provide | 11 |
novel pandemic | 11 |
study participants | 11 |
binding specificity | 11 |
significantly associated | 11 |
testing positive | 11 |
composite parameter | 11 |
mice infected | 11 |
two hospitals | 11 |
significantly different | 11 |
selective cox | 11 |
south america | 11 |
high prevalence | 11 |
severe respiratory | 11 |
inverse correlation | 11 |
transcription polymerase | 11 |
influenza incidence | 11 |
adenovirus type | 11 |
influenzae type | 11 |
sunshine duration | 11 |
randomly selected | 11 |
compound members | 10 |
monoclonal antibody | 10 |
genome sequencing | 10 |
least two | 10 |
local case | 10 |
review board | 10 |
nasal discharge | 10 |
specific siga | 10 |
coronavirus nl | 10 |
ae days | 10 |
large numbers | 10 |
human airway | 10 |
contact ferrets | 10 |
pilot study | 10 |
start date | 10 |
software version | 10 |
vaccine candidate | 10 |
highly significant | 10 |
weeks ahead | 10 |
influenzae non | 10 |
vaccination campaign | 10 |
research institute | 10 |
ci ae | 10 |
transmission rate | 10 |
european union | 10 |
cm protein | 10 |
york city | 10 |
resistant influenza | 10 |
institutional review | 10 |
adults aged | 10 |
financial support | 10 |
viruses may | 10 |
influenza detection | 10 |
decision making | 10 |
malaysian pilgrims | 10 |
influenza center | 10 |
natural history | 10 |
influenza rapid | 10 |
medical conditions | 10 |
nuclear translocation | 10 |
human population | 10 |
virus yield | 10 |
pollen concentrations | 10 |
historical data | 10 |
high level | 10 |
study staff | 10 |
respiratory rate | 10 |
molecular characterization | 10 |
hai antibody | 10 |
day lag | 10 |
different countries | 10 |
diseases among | 10 |
alert thresholds | 10 |
exact test | 10 |
mus tlr | 10 |
intranasal administration | 10 |
well plate | 10 |
genetic reassortment | 10 |
respiratory illnesses | 10 |
incidence rate | 10 |
donor percentage | 10 |
guinea pigs | 10 |
based influenza | 10 |
prospective study | 10 |
randomised controlled | 10 |
ari onset | 10 |
infected individuals | 10 |
general practice | 10 |
military recruits | 10 |
receptor specificity | 10 |
older children | 10 |
oropharyngeal swabs | 10 |
cell proliferation | 10 |
much higher | 10 |
incubation period | 10 |
previously published | 10 |
russian federation | 10 |
basic amino | 10 |
virus titer | 10 |
also shows | 10 |
taken together | 10 |
antigenic site | 10 |
infected human | 10 |
influenza activities | 10 |
findings suggest | 10 |
covid cases | 10 |
seasonal epidemics | 10 |
mrna splicing | 10 |
sequence data | 10 |
old female | 10 |
first imported | 10 |
active surveillance | 10 |
mass vaccination | 10 |
care facility | 10 |
virological surveillance | 10 |
post infection | 10 |
risk groups | 10 |
outpatient visits | 10 |
minor poultry | 10 |
viral na | 10 |
infectious dose | 10 |
time points | 10 |
years age | 10 |
across different | 10 |
family members | 10 |
patients seen | 10 |
conducted using | 10 |
emergency departments | 10 |
disease prevention | 10 |
east asia | 10 |
subtype influenza | 9 |
specific primers | 9 |
inflammatory response | 9 |
anomaly detection | 9 |
lung tissue | 9 |
antiviral coating | 9 |
viral transport | 9 |
viruses using | 9 |
pcr positive | 9 |
ns genes | 9 |
another study | 9 |
treatment coverage | 9 |
key points | 9 |
lung injury | 9 |
serial dilutions | 9 |
influenza thresholds | 9 |
clinical isolates | 9 |
iav infection | 9 |
ili among | 9 |
consecutive weeks | 9 |
influenza pandemics | 9 |
influenza viral | 9 |
human serum | 9 |
mass gatherings | 9 |
respiratory failure | 9 |
hai antibodies | 9 |
negative predictive | 9 |
wild birds | 9 |
multivariate analysis | 9 |
lg ha | 9 |
day care | 9 |
th week | 9 |
school closures | 9 |
northern hemisphere | 9 |
seasonal trends | 9 |
embryonated eggs | 9 |
acute febrile | 9 |
mouse model | 9 |
capital city | 9 |
immunosuppressive treatment | 9 |
illness onset | 9 |
respiratory distress | 9 |
original clinical | 9 |
health topics | 9 |
inactivated vaccines | 9 |
ili due | 9 |
among adults | 9 |
nasal wash | 9 |
elderly population | 9 |
significant difference | 9 |
march th | 9 |
virus vaccines | 9 |
mortality rates | 9 |
inflammatory cytokines | 9 |
relative risk | 9 |
see table | 9 |
positive cases | 9 |
total cohort | 9 |
viral strains | 9 |
confirmed viral | 9 |
na inhibitors | 9 |
specific mrna | 9 |
three waves | 9 |
google flu | 9 |
across states | 9 |
prior immunity | 9 |
previous years | 9 |
binding site | 9 |
air conditioning | 9 |
epidemiological surveillance | 9 |
high sensitivity | 9 |
sari surveillance | 9 |
fri cases | 9 |
potential conflicts | 9 |
observational study | 9 |
na activity | 9 |
european centre | 9 |
study using | 9 |
new zealand | 9 |
tested using | 9 |
using real | 9 |
risk communication | 9 |
viruses belonging | 9 |
reported among | 9 |
shared latrines | 9 |
univariate analysis | 9 |
described elsewhere | 9 |
antiviral efficacy | 9 |
basic reproductive | 9 |
different age | 9 |
log eid | 9 |
pandemic alert | 9 |
like receptor | 9 |
previous study | 9 |
antigenic characterization | 9 |
hemisphere influenza | 9 |
virus production | 9 |
absorbance values | 9 |
winter season | 9 |
subjects vaccinated | 9 |
syncytial viruses | 9 |
reference laboratory | 9 |
trivalent influenza | 9 |
sialic acid | 9 |
ferrets infected | 9 |
epidemic curves | 9 |
nice registry | 9 |
new protocol | 9 |
human cases | 9 |
greater accra | 9 |
wide range | 9 |
seasonal strains | 9 |
na inhibitor | 9 |
australian pilgrims | 9 |
older age | 9 |
correlation coefficient | 9 |
temporal model | 9 |
among malaysian | 9 |
viruses among | 9 |
simulation model | 9 |
time cell | 9 |
th century | 9 |
specific cd | 9 |
commonly used | 9 |
information criterion | 9 |
us centers | 9 |
two groups | 9 |
medical staff | 9 |
nucleotide sequences | 9 |
second week | 9 |
priority public | 9 |
pharmaceutical interventions | 9 |
research topics | 9 |
common among | 9 |
circulating viruses | 9 |
confirmed ph | 9 |
state i | 9 |
underlying conditions | 9 |
middle east | 9 |
studies conducted | 9 |
control study | 9 |
rainy season | 9 |
one dose | 9 |
triple reassortant | 9 |
ilinet data | 9 |
developed countries | 9 |
prospective cohort | 9 |
first local | 9 |
rate among | 9 |
different settings | 9 |
matrix gene | 9 |
vaccine development | 8 |
illness associated | 8 |
influenza subtype | 8 |
panel viruses | 8 |
pharmaceutical substances | 8 |
patients admitted | 8 |
pdm influenza | 8 |
similar results | 8 |
accra region | 8 |
recombinant strain | 8 |
data regarding | 8 |
virus subtype | 8 |
like symptoms | 8 |
pulmonary disease | 8 |
analyzed using | 8 |
chronic respiratory | 8 |
winter summer | 8 |
seasonal human | 8 |
cytoplasmic tail | 8 |
seeking behaviour | 8 |
aerosol transmission | 8 |
additional information | 8 |
female balb | 8 |
ili values | 8 |
respir viruses | 8 |
guinea pig | 8 |
cross protection | 8 |
also reported | 8 |
virus isolated | 8 |
oseltamivir treatment | 8 |
earlier studies | 8 |
nursing home | 8 |
positivity rate | 8 |
coated respirators | 8 |
virus types | 8 |
ili definitions | 8 |
na mutations | 8 |
antiviral therapy | 8 |
adjuvanted clade | 8 |
primary health | 8 |
type ii | 8 |
reported previously | 8 |
ae nm | 8 |
among influenza | 8 |
immunocompromised patients | 8 |
stool samples | 8 |
new rat | 8 |
hi titers | 8 |
also detected | 8 |
strains isolated | 8 |
military personnel | 8 |
chronic illnesses | 8 |
test results | 8 |
several limitations | 8 |
warning system | 8 |
children hospitalized | 8 |
bacterial species | 8 |
accession numbers | 8 |
antiviral activity | 8 |
multiplex real | 8 |
assay kit | 8 |
migratory birds | 8 |
laboratory data | 8 |
also used | 8 |
specific antibodies | 8 |
risk factor | 8 |
national surveillance | 8 |
mucosal immunity | 8 |
prevalence estimates | 8 |
monitoring system | 8 |
asian countries | 8 |
acute lung | 8 |
meteorological parameters | 8 |
herd immunity | 8 |
acute onset | 8 |
human subjects | 8 |
monitoring influenza | 8 |
vaccinated animals | 8 |
probe set | 8 |
methods used | 8 |
acute ili | 8 |
widely used | 8 |
patients presenting | 8 |
hospitalized children | 8 |
level risk | 8 |
supplementary table | 8 |
age distribution | 8 |
data obtained | 8 |
ili episode | 8 |
median week | 8 |
average viral | 8 |
allowed us | 8 |
respiratory symptom | 8 |
pcr detection | 8 |
like lineage | 8 |
vaccination rate | 8 |
search query | 8 |
case report | 8 |
master mix | 8 |
flow cytometry | 8 |
avian flu | 8 |
annual influenza | 8 |
virus lineages | 8 |
type i | 8 |
virus shedding | 8 |
flu trends | 8 |
plos one | 8 |
descriptive statistics | 8 |
ha titres | 8 |
normalized absorbance | 8 |
naturally acquired | 8 |
communicable diseases | 8 |
bacterial pathogens | 8 |
health emergencies | 8 |
cdc protocol | 8 |
vaccination program | 8 |
simple method | 8 |
limited number | 8 |
viral mrna | 8 |
aluminum hydroxide | 8 |
advisory committee | 8 |
antiviral intervention | 8 |
blood service | 8 |
multiplex rt | 8 |
east respiratory | 8 |
acid substitutions | 8 |
seasonal variation | 8 |
investigation forms | 8 |
specimens collected | 8 |
throat swab | 8 |
outpatient consultations | 8 |
pandemic preparedness | 8 |
children years | 8 |
determine whether | 8 |
derived reassortants | 8 |
cellular immune | 8 |
specific ili | 8 |
mean ic | 8 |
viral antigen | 8 |
standard deviations | 8 |
atypical bacteria | 8 |
old age | 8 |
epidemic weeks | 8 |
viral isolates | 8 |
influenza testing | 8 |
low level | 8 |
airway epithelium | 8 |
cases among | 8 |
seasonal flu | 8 |
uninfected cells | 8 |
hygiene measures | 8 |
final version | 8 |
parameter estimates | 8 |
red blood | 8 |
preventative measures | 8 |
st century | 8 |
virus titration | 8 |
binding preference | 8 |
surveillance networks | 8 |
nasopharyngeal aspirates | 8 |
attack rates | 8 |
different influenza | 8 |
assay using | 8 |
ae among | 8 |
low rank | 8 |
genetic analysis | 8 |
reduced susceptibility | 8 |
genome types | 8 |
eurasian avian | 8 |
patients among | 8 |
singapore military | 8 |
partial protection | 8 |
viruses associated | 8 |
long term | 8 |
ae mg | 8 |
reported ili | 8 |
routine surveillance | 8 |
influenza reference | 8 |
heart disease | 8 |
low reactors | 8 |
influenza disease | 8 |
final model | 8 |
epidemic influenza | 8 |
side effects | 8 |
two methods | 8 |
pandemic period | 8 |
influenza antigen | 8 |
diagnostic tests | 8 |
blown specimens | 8 |
inoculated intranasally | 8 |
vaccination hi | 8 |
blood donors | 8 |
patients without | 8 |
several studies | 7 |
various organs | 7 |
ili rate | 7 |
two days | 7 |
calculated using | 7 |
six internal | 7 |
available data | 7 |
haemagglutination inhibition | 7 |
threshold values | 7 |
negative samples | 7 |
drug susceptibility | 7 |
per cent | 7 |
version ae | 7 |
case fatality | 7 |
will also | 7 |
linear regression | 7 |
virus containing | 7 |
clinical information | 7 |
performed according | 7 |
influenza respiratory | 7 |
using icu | 7 |
foster city | 7 |
alert threshold | 7 |
viruses tested | 7 |
antibody titer | 7 |
total rna | 7 |
poisson model | 7 |
influenza patients | 7 |
global pandemic | 7 |
york state | 7 |
virologic data | 7 |
economic burden | 7 |
incubation time | 7 |
surveillance sites | 7 |
quality control | 7 |
results obtained | 7 |
antigen tests | 7 |
viral growth | 7 |
care providers | 7 |
acute lower | 7 |
lung disease | 7 |
global spread | 7 |
air pollutants | 7 |
last years | 7 |
global burden | 7 |
may represent | 7 |
mild ili | 7 |
serum specimens | 7 |
viral etiologies | 7 |
cleavage motif | 7 |
streptococcus pneumoniae | 7 |
first week | 7 |
gene constellation | 7 |
seroprotection rates | 7 |
provide evidence | 7 |
temperate regions | 7 |
dual respiratory | 7 |
rapid diagnostic | 7 |
winter school | 7 |
eastern china | 7 |
coated respirator | 7 |
observed ili | 7 |
using specific | 7 |
severe complications | 7 |
times higher | 7 |
ha sequences | 7 |
american countries | 7 |
immune protection | 7 |
ili influenza | 7 |
adenovirus infections | 7 |
written consent | 7 |
sanofi pasteur | 7 |
novel virus | 7 |
participants reported | 7 |
childhood pneumonia | 7 |
state level | 7 |
mean concentration | 7 |
military training | 7 |
influenza negative | 7 |
nucleotide sequence | 7 |
second season | 7 |
elderly patients | 7 |
noise ratio | 7 |
clade ae | 7 |
three influenza | 7 |
acid residues | 7 |
observed among | 7 |
model predictions | 7 |
post inoculation | 7 |
fluvac study | 7 |
viral agents | 7 |
master donor | 7 |
hospitalized cases | 7 |
like virus | 7 |
control strategies | 7 |
especially among | 7 |
pathogenic influenza | 7 |
kong sar | 7 |
influenza scenario | 7 |
body temperature | 7 |
negative patients | 7 |
also tested | 7 |
like swine | 7 |
three seasons | 7 |
provide data | 7 |
rank mc | 7 |
asymptomatic individuals | 7 |
clinical study | 7 |
also compared | 7 |
health officials | 7 |
staphylococcus aureus | 7 |
enterovirus genotypes | 7 |
par agonists | 7 |
demographic data | 7 |
series analysis | 7 |
new pandemic | 7 |
study subjects | 7 |
authors declare | 7 |
ili reporting | 7 |
latrine use | 7 |
requiring hospitalization | 7 |
using spss | 7 |
recombinant viruses | 7 |
temporal mc | 7 |
significance level | 7 |
influenza severity | 7 |
uri cases | 7 |
neuraminidase activity | 7 |
demographic factors | 7 |
time point | 7 |
credible set | 7 |
diagnostic testing | 7 |
epidemic doubling | 7 |
influenza prevalence | 7 |
life cycle | 7 |
ic kit | 7 |
cell surface | 7 |
serfling method | 7 |
infectious viruses | 7 |
inactivated whole | 7 |
case investigation | 7 |
health protection | 7 |
old group | 7 |
children enrolled | 7 |
multivariable logistic | 7 |
ph ae | 7 |
study suggests | 7 |
preclinical testing | 7 |
recommended vaccines | 7 |
infectious latent | 7 |
significant inverse | 7 |
based study | 7 |
current study | 7 |
generated using | 7 |
immunomodulatory agents | 7 |
weekly number | 7 |
every year | 7 |
virus stocks | 7 |
initial case | 7 |
antigen test | 7 |
positive results | 7 |
single infection | 7 |
clinical course | 7 |
acid sequence | 7 |
currently circulating | 7 |
allows us | 7 |
retrospective analysis | 7 |
demographic characteristics | 7 |
respiratory surveillance | 7 |
south african | 7 |
previous findings | 7 |
par stimulation | 7 |
better understanding | 7 |
recommendation system | 7 |
fatality rates | 7 |
viral genome | 7 |
higher rates | 7 |
novel infectious | 7 |
positive influenza | 7 |
hospital stay | 7 |
early stage | 7 |
new jersey | 7 |
clinical cases | 7 |
ili surges | 7 |
igv domain | 7 |
laboratory diagnosis | 7 |
per day | 7 |
contract hhsn | 7 |
tm influenza | 7 |
serum hai | 7 |
decision support | 7 |
chickens inoculated | 7 |
ct value | 7 |
first case | 7 |
traditional disease | 7 |
weekly percentage | 7 |
hi test | 7 |
virus antigen | 7 |
search engine | 7 |
pathogens detected | 7 |
symptoms suggestive | 7 |
also showed | 7 |
mycoplasma pneumoniae | 7 |
apoptotic response | 7 |
french pilgrims | 7 |
cartography construction | 7 |
dry cough | 7 |
inclusion criteria | 7 |
virus ha | 7 |
patient management | 7 |
ili samples | 7 |
longer time | 7 |
clinical practice | 7 |
study participant | 7 |
osv cam | 7 |
pandemic year | 7 |
received influenza | 7 |
individuals aged | 7 |
rna segment | 7 |
seasonal peak | 7 |
disease monitoring | 7 |
viral aetiology | 7 |
influenza infected | 7 |
health systems | 7 |
hypogammaglobulinemic patients | 7 |
i i | 7 |
significant increases | 7 |
complete picture | 7 |
actual use | 7 |
june th | 7 |
fold lower | 7 |
results indicated | 7 |
pcr system | 7 |
hypogammaglobulinemia patients | 7 |
seasonal epidemic | 7 |
transmission dynamics | 7 |
mass gathering | 7 |
also investigated | 7 |
west africa | 7 |
provide early | 7 |
data provided | 7 |
hi assay | 7 |
neutralizing antibody | 7 |
detected viruses | 7 |
subjective fever | 7 |
human pandemic | 7 |
antibody titres | 7 |
na subtypes | 7 |
sentinel gp | 7 |
positive episodes | 7 |
human cells | 7 |
resistance testing | 7 |
elisa method | 7 |
single infections | 7 |
drinking water | 7 |
health agencies | 7 |
immunization practices | 7 |
genetic characterization | 7 |
potential pathogens | 7 |
data showed | 7 |
military populations | 7 |
virus circulating | 7 |
ciliated cells | 7 |
normal distribution | 7 |
communicable disease | 7 |
schoolchildren aged | 7 |
using influenza | 7 |
virus challenge | 7 |
year olds | 7 |
mitigation measures | 7 |
last week | 7 |
pcr using | 7 |
chemiluminescent assays | 7 |
schlieren imaging | 7 |
large number | 7 |
ha titer | 7 |
clinical management | 7 |
peptides derived | 6 |
human volunteers | 6 |
ili percentage | 6 |
reporting system | 6 |
early phase | 6 |
coronavirus hku | 6 |
healthy preschool | 6 |
two studies | 6 |
leading cause | 6 |
years ago | 6 |
different clinical | 6 |
erk pathway | 6 |
viral protein | 6 |
virus pb | 6 |
infection rates | 6 |
transmission rates | 6 |
common symptoms | 6 |
care workers | 6 |
antibody titre | 6 |
relatively small | 6 |
molecular techniques | 6 |
data presented | 6 |
population size | 6 |
one doi | 6 |
efficacy trial | 6 |
medical indications | 6 |
pr virus | 6 |
study provides | 6 |
antigen detection | 6 |
data show | 6 |
febrile illness | 6 |
roche flx | 6 |
specific antibody | 6 |
rv detection | 6 |
preventing influenza | 6 |
illness cases | 6 |
alignment editor | 6 |
consecutive influenza | 6 |
analysis revealed | 6 |
south wales | 6 |
investigation team | 6 |
virus positivity | 6 |
common causes | 6 |
pediatric population | 6 |
dual resistant | 6 |
severely ill | 6 |
virus detected | 6 |
lung tissues | 6 |
laboratory methods | 6 |
unadjusted ili | 6 |
second immunization | 6 |
phylogenetic methods | 6 |
antiviral effect | 6 |
osv group | 6 |
following vaccination | 6 |
clinical studies | 6 |
care systems | 6 |
pollen concentration | 6 |
virus hemagglutinin | 6 |
inhibitor resistance | 6 |
ic determination | 6 |
investigate whether | 6 |
test positive | 6 |
porto alegre | 6 |
tympanic temperature | 6 |
one patient | 6 |
dynamic range | 6 |
tcid assay | 6 |
resistant seasonal | 6 |
good agreement | 6 |
pcr amplification | 6 |
virus surveillance | 6 |
highest risk | 6 |
reassortant influenza | 6 |
evolutionary genomics | 6 |
predict influenza | 6 |
severe clinical | 6 |
typical seasonal | 6 |
human disease | 6 |
study shows | 6 |
study protocol | 6 |
risk perception | 6 |
pneumonia among | 6 |
ec values | 6 |
clinical diagnosis | 6 |
gene sequence | 6 |
protein content | 6 |
first cases | 6 |
randomized trial | 6 |
asymptomatic controls | 6 |
proposed passive | 6 |
hadv infection | 6 |
ferrets inoculated | 6 |
index case | 6 |
age children | 6 |
reported elsewhere | 6 |
virus evolution | 6 |
influenza diagnosis | 6 |
ns proteins | 6 |
avg cusum | 6 |
data support | 6 |
first year | 6 |
vaccine based | 6 |
clinical influenza | 6 |
suspected case | 6 |
molecular evolutionary | 6 |
aged months | 6 |
universal transport | 6 |
infectious period | 6 |
ion channel | 6 |
different groups | 6 |
health services | 6 |
sera collected | 6 |
comparative epidemiology | 6 |
human cell | 6 |
outbreak investigation | 6 |
study demonstrated | 6 |
ae mm | 6 |
random effect | 6 |
recombinant protein | 6 |
cell tropism | 6 |
new south | 6 |
seasonal ili | 6 |
high intensity | 6 |
less common | 6 |
recent studies | 6 |
high throughput | 6 |
tween ae | 6 |
respiratory signs | 6 |
using ili | 6 |
potential pathogen | 6 |
infect dis | 6 |
potential role | 6 |
virus influenza | 6 |
ns mrna | 6 |
progenitor identification | 6 |
three groups | 6 |
patients may | 6 |
next influenza | 6 |
pneumonia requiring | 6 |
neu aca | 6 |
covid case | 6 |
deaths due | 6 |
excess non | 6 |
cruise lines | 6 |
nat positive | 6 |
hai assay | 6 |
may result | 6 |
care seeking | 6 |
probably due | 6 |
proportion positive | 6 |
human coronaviruses | 6 |
clinical manifestations | 6 |
endothelial cell | 6 |
also positive | 6 |
transfected cells | 6 |
term care | 6 |
significant reduction | 6 |
may cause | 6 |
ae lgeid | 6 |
distance matrix | 6 |
related swine | 6 |
winter holidays | 6 |
resistant variants | 6 |
cells infected | 6 |
blood cells | 6 |
viral mrnas | 6 |
oral infection | 6 |
light emission | 6 |
genetically related | 6 |
collected data | 6 |
human research | 6 |
sari percentage | 6 |
discriminatory value | 6 |
virus cm | 6 |
across age | 6 |
cell signaling | 6 |
respiratory epithelial | 6 |
considered statistically | 6 |
prospective observational | 6 |
consecutive seasons | 6 |
also significantly | 6 |
broad range | 6 |
shared latrine | 6 |
influenza strain | 6 |
global epidemiological | 6 |
ili proportions | 6 |
statistical methods | 6 |
weekly influenza | 6 |
medical history | 6 |
kidney cells | 6 |
bronchial epithelial | 6 |
animal models | 6 |
family size | 6 |
emergency department | 6 |
melting curve | 6 |
results may | 6 |
exposed subjects | 6 |
rhinovirus infection | 6 |
weekly proportion | 6 |
surveillance project | 6 |
ha genes | 6 |
hospital admission | 6 |
respiratory pathogen | 6 |
specimens tested | 6 |
patients positive | 6 |
blown nasal | 6 |
sterilizing immunity | 6 |
negative correlation | 6 |
maximum likelihood | 6 |
fold higher | 6 |
donor strain | 6 |
normally distributed | 6 |
atypical bacterial | 6 |
early signals | 6 |
bigdye terminator | 6 |
publishing ltd | 6 |
percentage positive | 6 |
one year | 6 |
key terms | 6 |
hpai viruses | 6 |
may contribute | 6 |
pneumonia cases | 6 |
rate min | 6 |
aquatic birds | 6 |
illness incidence | 6 |
medically attended | 6 |
received tiv | 6 |
face masks | 6 |
patients aged | 6 |
influenza pathogenesis | 6 |
evolutionary genetics | 6 |
higher sensitivity | 6 |
childcare centres | 6 |
expected influenza | 6 |
adults admitted | 6 |
mean average | 6 |
mini kit | 6 |
blackwell publishing | 6 |
multivariate model | 6 |
model parameters | 6 |
female sex | 6 |
development core | 6 |
healthcare system | 6 |
critically ill | 6 |
analysed strains | 6 |
spread rapidly | 6 |
tertiary care | 6 |
isolation rates | 6 |
regression method | 6 |
na sequences | 6 |
donor virus | 6 |
subtypes among | 6 |
human adenoviruses | 6 |
time polymerase | 6 |
rapid diagnosis | 6 |
isolated viruses | 6 |
gsk vaccines | 6 |
phase i | 6 |
ili outpatients | 6 |
age range | 6 |
types subtypes | 6 |
healthcare settings | 6 |
confirmed human | 6 |
proinflammatory cytokines | 6 |
analysis showed | 6 |
older individuals | 6 |
clinical severity | 6 |
three times | 6 |
genetics analysis | 6 |
influenza progenitor | 6 |
early identification | 6 |
study implementation | 6 |
domestic poultry | 6 |
live influenza | 6 |
surveillance period | 6 |
onset dates | 6 |
correlation coefficients | 6 |
sari influenza | 6 |
outpatient clinics | 6 |
infection cases | 6 |
seroprotection rate | 6 |
seasonal pattern | 6 |
virus dilutions | 6 |
also observed | 6 |
epidemic growth | 6 |
two major | 6 |
matrix protein | 6 |
data quality | 6 |
viral mono | 6 |
absolute humidity | 6 |
search activity | 6 |
temporal distribution | 6 |
prospective surveillance | 6 |
respiratory secretions | 6 |
molecular markers | 6 |
correlation analysis | 6 |
later waves | 6 |
publicly available | 6 |
better understand | 6 |
study included | 6 |
mortality associated | 6 |
control mice | 6 |
antibiotic use | 6 |
showed high | 6 |
clinical reports | 6 |
emergency rooms | 6 |
recent pandemic | 6 |
reassortant virus | 6 |
query data | 6 |
like seasonality | 6 |
care units | 6 |
geographic cartography | 6 |
reactive antibodies | 6 |
verbal consent | 6 |
kindly provided | 6 |
exit screening | 6 |
ae sd | 6 |
lung lesions | 6 |
viruses including | 6 |
mice treated | 6 |
challenge studies | 6 |
cohort studies | 6 |
income countries | 6 |
viral particles | 6 |
composite variables | 6 |
administration costs | 6 |
high growth | 6 |
sentinel facilities | 6 |
routinely collected | 6 |
surveillance standards | 6 |
across studies | 6 |
infected lung | 6 |
ha peptide | 6 |
cases may | 6 |
pandemic response | 6 |
infected animals | 6 |
sentinel practitioners | 6 |
antiviral susceptibility | 6 |
disease symptoms | 6 |
sampling strategy | 6 |
ill patients | 6 |
white mice | 6 |
sentinel general | 6 |
bordetella pertussis | 6 |
environmental factors | 6 |
age category | 6 |
surveillance studies | 6 |
pcr testing | 6 |
surveillance among | 6 |
different pathogens | 6 |
core team | 6 |
rna segments | 6 |
ci upper | 6 |
cytokine induction | 6 |
total siga | 6 |
ill individuals | 6 |
swabs collected | 6 |
matrix completion | 6 |
us epidemic | 6 |
difficulty breathing | 6 |
high mortality | 6 |
avian viruses | 6 |
ili counts | 6 |
ae units | 6 |
basic reproduction | 6 |
nucleic acids | 6 |
virus activity | 6 |
summer school | 6 |
viral proteins | 6 |
virus rna | 6 |
dis doi | 6 |
viral fitness | 6 |
alaska cruise | 6 |
whether icu | 5 |
per season | 5 |
human alveolar | 5 |
subjects aged | 5 |
low number | 5 |
identified influenza | 5 |
demand parameter | 5 |
current surveillance | 5 |
research roadmap | 5 |
viral pneumonia | 5 |
lower risk | 5 |
data generated | 5 |
exposed household | 5 |
online supplementary | 5 |
confounding factors | 5 |
influenza seasonality | 5 |
infection dose | 5 |
sas institute | 5 |
limited data | 5 |
different strains | 5 |
hexon gene | 5 |
migratory waterfowl | 5 |
humoral inflammation | 5 |
dwelling older | 5 |
control ferrets | 5 |
among seasonal | 5 |
handwashing station | 5 |
influenza years | 5 |
university grants | 5 |
inflammation status | 5 |
igv plus | 5 |
bovine serum | 5 |
target cells | 5 |
based assays | 5 |
geographical regions | 5 |
serially diluted | 5 |
based studies | 5 |
puerto rico | 5 |
service members | 5 |
received two | 5 |
intranasal pathogenicity | 5 |
season influenza | 5 |
case reporting | 5 |
among military | 5 |
even higher | 5 |
patient visits | 5 |
strain selection | 5 |
healthy adults | 5 |
laboratory surveillance | 5 |
developed using | 5 |
lumped demand | 5 |
western blotting | 5 |
mean titers | 5 |
human parainfluenza | 5 |
weekly basis | 5 |
expert group | 5 |
recovery samples | 5 |
susceptibility testing | 5 |
hospitalised patients | 5 |
inactivated virus | 5 |
outpatient setting | 5 |
determined using | 5 |
virus compared | 5 |
excellence scheme | 5 |
pilgrims attending | 5 |
following virus | 5 |
body weights | 5 |
fast track | 5 |
well known | 5 |
virus induced | 5 |
induce apoptosis | 5 |
one another | 5 |
grant aoe | 5 |
monovalent vaccine | 5 |
children using | 5 |
clinical use | 5 |
specific influenza | 5 |
ili sari | 5 |
well established | 5 |
influenza samples | 5 |
large proportion | 5 |
transmission parameters | 5 |
seropositive proportion | 5 |
mortality data | 5 |
air sacs | 5 |
armed forces | 5 |
sari group | 5 |
standard method | 5 |
analysis based | 5 |
genetics derived | 5 |
health interventions | 5 |
ae eid | 5 |
serologic assays | 5 |
pandemic planning | 5 |
secondary infections | 5 |
spread across | 5 |
diamond princess | 5 |
immunocompromising conditions | 5 |
nhs organisations | 5 |
mononuclear cells | 5 |
statistical computing | 5 |
small proportion | 5 |
blood mononuclear | 5 |
major concern | 5 |
conceptual model | 5 |
mortem materials | 5 |
microvascular endothelial | 5 |
second wave | 5 |
laboratory samples | 5 |
results indicate | 5 |
hajj years | 5 |
one month | 5 |
disease caused | 5 |
molecular methods | 5 |
received travel | 5 |
dimensional map | 5 |
dutch population | 5 |
inversely correlated | 5 |
also performed | 5 |
mild symptoms | 5 |
sequence alignments | 5 |
base case | 5 |
studies involving | 5 |
research council | 5 |
based hierarchical | 5 |
high viral | 5 |
standardized questionnaire | 5 |
also included | 5 |
spss inc | 5 |
cell immunoglobulin | 5 |
although influenza | 5 |
definition used | 5 |
imported case | 5 |
subjects born | 5 |
peak titers | 5 |
longitudinal study | 5 |
clear seasonality | 5 |
previous reports | 5 |
million people | 5 |
immunization programs | 5 |
outbreak detection | 5 |
exhaled airflows | 5 |
obstructive pulmonary | 5 |
since influenza | 5 |
virological characteristics | 5 |
suspected influenza | 5 |
virus propagation | 5 |
contact transmission | 5 |
credible interval | 5 |
standard protocol | 5 |
national ethics | 5 |
dendritic cells | 5 |
exponentially weighted | 5 |
neuraminidase inhibition | 5 |
lung microvascular | 5 |
pandemic phase | 5 |
climate change | 5 |
sc treated | 5 |
epidemic weekly | 5 |
potential confounders | 5 |
additive poisson | 5 |
five priority | 5 |
like epidemics | 5 |
quarantine station | 5 |
chlamydophila pneumoniae | 5 |
control methods | 5 |
local health | 5 |
pandemic mortality | 5 |
chronic medical | 5 |
among pediatric | 5 |
sentinel network | 5 |
five years | 5 |
retrospective study | 5 |
results highlight | 5 |
np protein | 5 |
influenza research | 5 |
patients tested | 5 |
individuals infected | 5 |
screening success | 5 |
may vary | 5 |
drastically reduced | 5 |
general symptoms | 5 |
first patient | 5 |
nt assays | 5 |
control animals | 5 |
gp registry | 5 |
human health | 5 |
escherichia coli | 5 |
potential risk | 5 |
serum antibody | 5 |
slightly higher | 5 |
cultures tested | 5 |
weighted moving | 5 |
fully susceptible | 5 |
research team | 5 |
trivalent inactivated | 5 |
medical attention | 5 |
two additional | 5 |
elementary schools | 5 |
systematic sampling | 5 |
behavioral responses | 5 |
statistical model | 5 |
vascular dysfunction | 5 |
universal influenza | 5 |
containing ae | 5 |
summer holiday | 5 |
vietnamese children | 5 |
two sites | 5 |
proct values | 5 |
transport media | 5 |
medium supplemented | 5 |
routine influenza | 5 |
animal model | 5 |
trained medical | 5 |
odds ratio | 5 |
animal influenza | 5 |
highly attenuated | 5 |
infected pigs | 5 |
cdc data | 5 |
virus group | 5 |
vaccine doses | 5 |
final concentration | 5 |
rapidly throughout | 5 |
adjusted average | 5 |
patients treated | 5 |
growth kinetics | 5 |
temperate climate | 5 |
collected using | 5 |
getting sick | 5 |
mitigation strategies | 5 |
existing surveillance | 5 |
several years | 5 |
positive specimens | 5 |
host range | 5 |
daily basis | 5 |
measures among | 5 |
like strains | 5 |
uncoated ffp | 5 |
study influenza | 5 |
semana epidemiologica | 5 |
virus used | 5 |
human infections | 5 |
adaptive immunity | 5 |
policy makers | 5 |
ae tcid | 5 |
three dimensional | 5 |
years compared | 5 |
also recommended | 5 |
essential role | 5 |
na enzyme | 5 |
poultry species | 5 |
infection status | 5 |
laboratory analysis | 5 |
little impact | 5 |
mice injected | 5 |
domestic waterfowl | 5 |
mediated immunity | 5 |
assays using | 5 |
na subtype | 5 |
virology laboratory | 5 |
prescribed antibiotics | 5 |
government department | 5 |
detailed data | 5 |
surveillance pilot | 5 |
pandemic laiv | 5 |
previous report | 5 |
registered ili | 5 |
semanal semana | 5 |
asymptomatic infections | 5 |
iranian pilgrims | 5 |
genetic analyzer | 5 |
goat anti | 5 |
detection methods | 5 |
threshold value | 5 |
tecumseh study | 5 |
mucosal immunization | 5 |
stop solution | 5 |
biological samples | 5 |
human rhinoviruses | 5 |
influenza circulation | 5 |
study suggest | 5 |
modern tools | 5 |
old chickens | 5 |
specimens per | 5 |
bootstrap value | 5 |
resistant pandemic | 5 |
south korea | 5 |
ili rates | 5 |
age years | 5 |
potential effects | 5 |
mix hybrid | 5 |
seasonal thresholds | 5 |
provide protection | 5 |
pediatric patients | 5 |
hi matrix | 5 |
following criteria | 5 |
lower compared | 5 |
based transmission | 5 |
ethical approval | 5 |
cusum method | 5 |
care physicians | 5 |
plaque assays | 5 |
second part | 5 |
pigs inoculated | 5 |
laboratory animals | 5 |
protective measures | 5 |
different time | 5 |
conjugate vaccine | 5 |
fattening farms | 5 |
high diversity | 5 |
among us | 5 |
reported cases | 5 |
viruses used | 5 |
significant morbidity | 5 |
clinical testing | 5 |
provided evidence | 5 |
superscript iii | 5 |
episodes positive | 5 |
progenitor genes | 5 |
human virus | 5 |
legionella pneumophila | 5 |
virus identification | 5 |
distinct lineages | 5 |
among iranian | 5 |
volunteer challenge | 5 |
low virus | 5 |
time course | 5 |
biosafety level | 5 |
hajj seasons | 5 |
mean ae | 5 |
hay fever | 5 |
influenza positivity | 5 |
disease transmission | 5 |
missing values | 5 |
virus showed | 5 |
commonly isolated | 5 |
clinical infections | 5 |
nhs london | 5 |
winter influenza | 5 |
environmental tobacco | 5 |
multiple viral | 5 |
influenza panel | 5 |
health indications | 5 |
human rhinovirus | 5 |
including pneumonia | 5 |
randomized controlled | 5 |
onset within | 5 |
yield reassortants | 5 |
corrected post | 5 |
fecal droppings | 5 |
epidemic dynamics | 5 |
strains circulating | 5 |
gmt ae | 5 |
training period | 5 |
epidemic periods | 5 |
different populations | 5 |
generalized linear | 5 |
plasmapheresis capacity | 5 |
multiplex polymerase | 5 |
hospital mortality | 5 |
data using | 5 |
protective efficacy | 5 |
aged care | 5 |
virologic surveillance | 5 |
illness sentinel | 5 |
necessarily represent | 5 |
alcoholic hand | 5 |
viruses will | 5 |
pigs per | 5 |
csl ltd | 5 |
vaccine showed | 5 |
us military | 5 |
cost data | 5 |
common cold | 5 |
outpatient ili | 5 |
reassortant swine | 5 |
containment phase | 5 |
health intervention | 5 |
molecular studies | 5 |
induces protective | 5 |
data available | 5 |
cell viability | 5 |
clinical illness | 5 |
time lags | 5 |
ectopic trypsin | 5 |
outcome variable | 5 |
also calculated | 5 |
cases reported | 5 |
ni susceptibility | 5 |
culture technique | 5 |
study aims | 5 |
among school | 5 |
epidemic thresholds | 5 |
clinical predictors | 5 |
immunoglobulin mucin | 5 |
ship passengers | 5 |
standard procedures | 5 |
significant predictors | 5 |
new ili | 5 |
sentinel site | 5 |
factors among | 5 |
emerging influenza | 5 |
hand rubs | 5 |
mean body | 5 |
short period | 5 |
reducing influenza | 5 |
viral titer | 5 |
dependent manner | 5 |
peak occurrence | 5 |
multivariate logistic | 5 |
elderly individuals | 5 |
conducted among | 5 |
children within | 5 |
acute viral | 5 |
full length | 5 |
another limitation | 5 |
full model | 5 |
home visit | 5 |
hierarchical clustering | 5 |
known cause | 5 |
laboratory capacity | 5 |
surveillance activities | 5 |
suspension cell | 5 |
ev genotypes | 5 |
high frequency | 5 |
diagnostic accuracy | 5 |
developed severe | 5 |
oseltamivir prophylaxis | 5 |
recent years | 5 |
vaccine group | 5 |
challenge virus | 5 |
epidemiological parameters | 5 |
related illness | 5 |
ship respiratory | 5 |
latin america | 5 |
cd ifnc | 5 |
onto antigenic | 5 |
cytopathic effects | 5 |
categorical variables | 5 |
low rates | 5 |
ili group | 5 |
model using | 5 |
unusual severity | 5 |
specific immune | 5 |
index monitoring | 5 |
transmission within | 5 |
including covid | 5 |
infected group | 5 |
time trend | 5 |
adapted viruses | 5 |
nai distribution | 5 |
internet searches | 5 |
influenza episodes | 5 |
investigated whether | 5 |
submitting specimens | 5 |
early epidemic | 5 |
children months | 5 |
period began | 5 |
pcr master | 5 |
distress syndrome | 5 |
smoking status | 5 |
type viruses | 5 |
odds ratios | 5 |
income settings | 5 |
subtype viruses | 5 |
hoc sampling | 5 |
microscopic observation | 5 |
social contact | 5 |
time surveillance | 5 |
previous infection | 5 |
using primers | 5 |
week ending | 5 |
host immune | 5 |
transmission characteristics | 5 |
nv ca | 5 |
regional health | 5 |
poultry markets | 5 |
pseudomonas aeruginosa | 5 |
schlieren images | 5 |
proct levels | 5 |
ii rv | 5 |
statistically significantly | 5 |
also obtained | 5 |
two vaccine | 5 |
secondary household | 5 |
assay sensitivity | 5 |
cases will | 5 |
infections due | 5 |
viral pathogen | 5 |
fold rise | 5 |
existing immunity | 5 |
developing secondary | 5 |
influenza isolates | 5 |
two sentinel | 5 |
health promotion | 5 |
crowded places | 5 |
average peak | 5 |
symptoms associated | 5 |
cytokine responses | 5 |
lethality rate | 5 |
protection hypothesis | 5 |
host cell | 5 |
tobacco smoke | 5 |
also increased | 5 |
malaysian hajj | 5 |
reliable data | 5 |
molecular diagnosis | 5 |
weeks later | 5 |
epidemic peak | 5 |
jak signaling | 5 |
per infections | 5 |
washington state | 5 |
health doi | 5 |
lower prevalence | 5 |
strains identified | 5 |
genome type | 5 |
around ae | 5 |
higher ha | 5 |
south american | 5 |
influenza case | 5 |
index cases | 5 |
fourth wave | 5 |
pharyngeal swabs | 5 |
one hundred | 5 |
thai army | 5 |
plate format | 5 |
ae ci | 5 |
much lower | 5 |
point estimates | 5 |
transmission among | 5 |
acquired influenza | 5 |
episode onset | 5 |
egg production | 5 |
among french | 5 |
primary schools | 5 |
likely due | 5 |
success rate | 5 |
related costs | 5 |
abi prism | 5 |
including human | 5 |
people aged | 5 |
considered significant | 5 |
xicheng district | 5 |
peak period | 5 |
values obtained | 5 |
genetic changes | 5 |
first influenza | 5 |
multicenter study | 5 |
strongly suggest | 5 |
cytokine dysregulation | 5 |
gene sequences | 5 |
pcr negative | 5 |
five times | 5 |
ili associated | 5 |
similar findings | 5 |
specific real | 5 |
anomaly incidence | 5 |
chronic obstructive | 5 |
pcr products | 5 |
geographic specific | 5 |
novel genotypes | 5 |
imported cases | 5 |
close contact | 5 |
accurate estimates | 5 |
community epidemiology | 5 |
incidence per | 5 |
influenza year | 5 |
gene pool | 5 |
copy number | 5 |
influenza data | 5 |
plasma membrane | 5 |
vp sequences | 5 |
hemagglutinin inhibition | 5 |
ili reported | 5 |
costs associated | 5 |
infection rate | 5 |
american avian | 5 |
weekly counts | 4 |
sectional study | 4 |
fatal pneumonia | 4 |
like season | 4 |
vaccination titers | 4 |
temperature cut | 4 |
allantoic inoculation | 4 |
four viruses | 4 |
oceanian avian | 4 |
counts across | 4 |
contact pigs | 4 |
significantly correlated | 4 |
medical center | 4 |
initial epidemic | 4 |
virus infectivity | 4 |
rt pcr | 4 |
birth weight | 4 |
infection symptoms | 4 |
day doubling | 4 |
early diagnosis | 4 |
health risks | 4 |
drifted influenza | 4 |
culture derived | 4 |
sas version | 4 |
based tours | 4 |
antiviral potential | 4 |
search index | 4 |
fairly similar | 4 |
vaccine viruses | 4 |
clustering method | 4 |
vaccinated participants | 4 |
whole genome | 4 |
serum antibodies | 4 |
replication kinetics | 4 |
viral interference | 4 |
optimised design | 4 |
infection may | 4 |
showed similar | 4 |
world data | 4 |
seek medical | 4 |
one child | 4 |
like ha | 4 |
working group | 4 |
severity estimates | 4 |
detection system | 4 |
ainfected cells | 4 |
chemiluminescent neuraminidase | 4 |
vero cells | 4 |
species hadv | 4 |
mrna expression | 4 |
study demonstrates | 4 |
expected prevalence | 4 |
multivariate models | 4 |
coryzal symptoms | 4 |
pandemic situation | 4 |
donor ferrets | 4 |
sampling methods | 4 |
secular trend | 4 |
health behaviors | 4 |
young adult | 4 |
acquired protection | 4 |
among small | 4 |
age cohort | 4 |
disease association | 4 |
wide passive | 4 |
pandemic diseases | 4 |
seasonal baseline | 4 |
two seasons | 4 |
patients older | 4 |
seasonal viruses | 4 |
two ferrets | 4 |
significant number | 4 |
lower transmissibility | 4 |
viruses identified | 4 |
previously infected | 4 |
underlying risk | 4 |
virus culture | 4 |
open access | 4 |
three patients | 4 |
uncoated respirators | 4 |
ffp respirator | 4 |
rate ratio | 4 |
antibiotic resistance | 4 |
possible explanation | 4 |
resistant isolates | 4 |
following challenge | 4 |
constitutional symptoms | 4 |
rhinovirus outbreak | 4 |
whole virus | 4 |
strain pr | 4 |
endemic swine | 4 |